About ELIOS Vision
ELIOS Vision is a Healthcare company based in Los Angeles (United States) founded in 2019 by Thomas F Neuhann and Richard A Lewis, and was acquired by Bausch & Lomb in December 2024. It operates as an excimer laser technology is applied to develop glaucoma therapy devices. ELIOS Vision offers products and services including ELIOS and FIDO Laser Applicator. Its focus areas include Life Sciences, Ophthalmology, Medical Devices and Therapy. Its legal entity is ELIOS VISION, INC. Its competitors include ViaLase, BELKIN Vision, Radiance Therapeutics and EyeLight; 3 of its 4 listed competitors have raised funding.
Company details
ELIOS Vision was established in 2019 in Los Angeles, United States, within the medical device sector focused on ophthalmology. An excimer laser-based device known as ELIOS ELT is developed for micro-invasive glaucoma surgery. Intraocular pressure in glaucoma patients is targeted for reduction through this technology. Operations center on advancing eye care treatments in the United States.
- Headquarters Los Angeles, United States
- Founders Thomas F Neuhann, Richard A Lewis
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website eliosvision.com
- Social LinkedIn X Facebook Instagram
- Acquired by Bausch & Lomb (Dec 2024)
- Legal Name Elios Vision, Inc.
- Investors
- Acquired byBausch & Lomb
(Dec 2024)
Products & Services of ELIOS Vision
ELIOS Vision offers a comprehensive portfolio of products and services, including ELIOS and FIDO Laser Applicator.
CE-marked device for treating glaucoma in adult patients.
Applicator for medical laser applications in healthcare.
Funding Insights of ELIOS Vision
- Total Rounds 1
All 1 funding rounds of ELIOS Vision with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2022 | – | Debt – Conventional | – | – | – |
1 investors in total: 1 institutional.
Investors in ELIOS Vision
ELIOS Vision has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Bausch & Lomb.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Ophthalmic pharmaceuticals and instruments are developed for eye care. | 1853 | bausch.com | Bridgewater, United States |
Investor details for ELIOS Vision
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of ELIOS Vision
9 people are tracked at ELIOS Vision (9 in leadership).
| Name | Role | Group |
|---|---|---|
Thomas F Neuhann | Co-Founder | Leadership |
Richard A Lewis | Co-Founder | Leadership |
Angela Pastick | Director, Quality Assurance And Compliance | Leadership |
Arieh Zak | Senior Vp, Regulatory, Quality & Clinical Affairs | Leadership |
Elliot Friedman | CEO | Leadership |
Melissa Moe | Director, Clinical Affairs | Leadership |
Cari Stone | Chief Marketing Officer | Leadership |
Rupali Nangia | Vice President, Clinical & Regulatory Affairs | Leadership |
Steve Hayes | Head Of Business Intelligence, EU | Leadership |
Complete people profiles for ELIOS Vision
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of ELIOS Vision
3 dated milestones of ELIOS Vision across 5 years, from founding to its latest funding, stage changes and deals.
- Founded ELIOS Vision is founded.
- Funding First funding round.
- Exit Acquired by Bausch & Lomb.
Competitors of ELIOS Vision
ELIOS Vision has 4 listed competitors in our database, 3 of them funded. They include ViaLase, BELKIN Vision, Radiance Therapeutics and EyeLight, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| vialase.com | 2018 | Newport Beach, United States | $45.18M | – | Image-guided femtosecond laser devices for glaucoma treatments are developed. | |
| belkin-vision.com | 2013 | Yavne, Israel | $14.75M | – | Laser device for glaucoma treatment developed by BELKIN Vision. | |
| radiancetherapeutics.com | 2018 | Oro Valley, United States | $14M | – | Beta ophthalmic applicator for glaucoma surgery is developed. | |
| eyelight.us | 2004 | Carlsbad, United States | – | – | Develops patented treatment methods for glaucoma. |
Detailed competitors of ELIOS Vision
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of ELIOS Vision
The website of ELIOS Vision (eliosvision.com) receives about 1.7K visits a month.
- Monthly visits1.7K
▲ 17.8% vs previous month
Top companies in Ophthalmology
10 companies that operate in the same segment as ELIOS Vision (Ophthalmology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of a wide range of eye care products | 1945 | Fort Worth, Texas, United States | USD 171.61 M | USD 9.64 B | 25,600 | |
Genetic medicines are developed by 4DMT for transformative therapies. | 2013 | Emeryville, California, United States | USD 186.59 M | USD 85.21 M | 227 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 | |
Ophthalmic pharmaceuticals for diabetic macular edema are developed and commercialized. | 2003 | Alpharetta, Georgia, United States | USD 66.8 M | USD 80.75 M | 79 | |
AI-powered portable solutions for ophthalmic screening and diagnosis are developed. | 2009 | Bengaluru, Karnataka, India | USD 25.01 M | USD 4.85 M | 135 | |
Gene therapies for ocular and neurodegenerative diseases are developed. | 2015 | New York, New York, United States | – | USD 81.39 M | 381 | |
Small molecule therapeutics for ophthalmic disorders are developed. | 1987 | Watertown, United States | – | USD 31.37 M | 165 | |
Therapies for metabolic and orphan diseases are developed by Rezolute. | 2012 | Denver, Colorado, United States | – | – | 59 | |
Manufacturer of portable digital eye imaging devices and cloud-based healthcare platforms | 2010 | Bengaluru, Karnataka, India | USD 18.12 M | USD 4.78 M | 145 | |
Therapeutics for retinal diseases are developed by the company. | 2009 | Palo Alto, California, United States | USD 35.84 M | – | 109 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Elios Vision
Complete news archive for ELIOS Vision
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ELIOS Vision
ELIOS Vision was founded in 2019 and raised its 1st funding round 3 years after it was founded.
ELIOS Vision is headquartered in Los Angeles, United States. It is registered at Los Angeles, California, United States.
ELIOS Vision was established in 2019 in Los Angeles, United States, within the medical device sector focused on ophthalmology. An excimer laser-based device known as ELIOS ELT is developed for micro-invasive glaucoma surgery. Intraocular pressure in glaucoma patients is targeted for reduction through this technology. Operations center on advancing eye care treatments in the United States.
ELIOS Vision's top competitors include ViaLase, BELKIN Vision and Radiance Therapeutics.
ELIOS Vision offers ELIOS and FIDO Laser Applicator.
ELIOS Vision has 1 investor. Key investors include Bausch & Lomb.
ELIOS Vision operates through Elios Vision, Inc..
Yes. ELIOS Vision was acquired by Bausch & Lomb in December 2024.